



## Supplemental material


Shin et al., <https://doi.org/10.1084/jem.20172170>



**Figure S1. Transcriptome significance of PIP4K2A in GBM. (A and B)** Scatter plot showing linear correlation between *PIP4K2A* and *PTEN* mRNA expression levels in TCGA U133A microarray (left) and RNA sequencing (right) datasets. The P values were obtained using the Pearson correlation test. **(C and D)** Kaplan-Meier survival curve analysis of GBM patients based on the *PIP4K2A* mRNA expression level in TCGA (left) and Gravendeel et al. (2009) datasets (right). The P values were obtained using the two-sided log-rank test. \*,  $P \leq 0.05$ ; \*\*\*,  $P \leq 0.001$ .



**Figure S2. Effects of PIP4K2A in cellular growth.** **(A)** Effects of PIP4K2A overexpression or shRNA-mediated knockdown on cellular proliferation. The P values were calculated using the two-tailed Student's *t* test. **(B)** Immunoblot analysis of PIP4K2A, pAKT, and p85 in GBM cells that were transduced with either control or PIP4K2A shRNA. Actin was used as a loading control. **(C)** Proliferation assay of GBM cells from B. The P values were calculated using the two-tailed Student's *t* test. Values are presented as mean  $\pm$  SD ( $n = 4$ ). Data shown in A are representative of two independent and reproducible experiments. Data shown in B and C are representative of three independent and reproducible experiments. \*,  $P \leq 0.05$ .



**Figure S3. Effects of PIP4K2A and PTEN in PI3K signaling pathway.** **(A)** Immunoblot analysis of PIP4K2A, PTEN, and p85 in GBM cells. Actin was used as a loading control. **(B)** Immunoblot analysis of PIP4K2A and PTEN in GBM cells and NPCs that were transduced with either control or PIP4K2A. Actin was used as a loading control. **(C)** Immunoblot analysis of PIP4K2A, pAKT, and AKT in NPCs and GBMs that were transduced with either control of PIP4K2A. Actin was used as a loading control. **(D)** Co-IP of ubiquitin and p85 in GBM cells that were transduced with either PIP4K2A or control and treated with or without MG132. IgG represents a control antibody used for IPs. **(E)** Co-IP of ubiquitin and p85 in GBM cells that were transduced with either PTEN or control and treated with MG132. IgG represents a control antibody used for IPs. Data shown in A–E are representative of three independent and reproducible experiments. Endo., endogenous; Exo., exogenous; WB, Western blot.

## Oncomine dataset




Figure S4. **Clinical relevance of PIP4K2A in breast and lung cancers.** (A) Oncomine microarray data analysis for PIP4K2A expression in breast carcinoma versus normal breast tissues ( $P < 0.0007$ ). (B) Oncomine microarray data analysis for PIP4K2A expression in lung adenocarcinoma versus normal lung tissues ( $P < 0.02$ ). The P values were calculated by using the two-sided Wilcoxon rank sum test.




Figure S5. **Effects of PIP4K2A-kinase mutations in GBM.** (A) Immunoblot analysis of PIP4K2A and p85 in GBM cells that were transduced with control, PIP4K2A WT, PIP4K2A G131L mutation, PIP4K2A Y138F mutation, or PIP4K2A N251S mutation. Actin was used as a loading control. (B) Proliferation assay of GBM cells from A. Values are presented as mean  $\pm$  SD ( $n = 5$ ). The P values were calculated using the two-tailed Student's *t* test. \*\*\*,  $P \leq 0.001$ . Data shown in Figure A and B are representative of three independent and reproducible experiments.

## References

- Gravendeel, L.A., M.C. Kouwenhoven, O. Gevaert, J.J. de Rooij, A.P. Stubbs, J.E. Duijm, A. Daemen, F.E. Bleeker, L.B. Bralten, N.K. Kloosterhof, et al. 2009. Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology. *Cancer Res.* 69:9065–9072. <https://doi.org/10.1158/0008-5472.CAN-09-2307>